Every 10-Q that Aclaris Therapeutics, Inc. (ACRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics, Inc. reported Q2 2026 revenue of $1.629 million and a net loss of $21.505 million, bringing first‑half revenue to $3.625 million and net loss to $41.329 million. Performance reflects continued investment in immuno‑inflammatory programs including bosakitug, ATI‑052, modzatinib and ATI‑9494.
Research and development expenses were $18.066 million in Q2 and $33.723 million year‑to‑date, while general and administrative costs reached $6.048 million and $12.791 million. Other income of $2.733 million, mainly interest and non‑cash royalty income, partially offset a Q2 operating loss of $24.238 million.
Cash, cash equivalents and marketable securities totaled $170.6 million at June 30, 2026. Operating activities used $37.996 million of cash in the first half, largely balanced by $57.872 million from equity financing, including a March at‑the‑market sale; a further July ATM raised $40.2 million gross. Management states these resources fund operations for more than 12 months but anticipates ongoing losses and additional future capital needs.
Aclaris Therapeutics reported a larger quarterly loss as it ramped R&D on its immuno-inflammatory pipeline. For the three months ended March 31, 2026, revenue was $2.0 million, mainly from licensing and contract research, while net loss widened to $19.8 million from $15.1 million a year earlier.
Research and development expenses rose to $15.7 million, driven by ATI‑052 Phase 1 programs in atopic dermatitis and asthma, ATI‑9494 preclinical work, and broader discovery investments, partly offset by lower ATI‑2138 costs after a completed Phase 2a trial.
Aclaris strengthened its balance sheet by raising $57.9 million net through an at‑the‑market stock program, ending the quarter with $190.8 million in cash, cash equivalents and marketable securities and an accumulated deficit of $987.6 million. Management believes existing resources will fund operations for more than 12 months, while it continues to seek partnerships and potential royalty monetizations to support development of bosakitug, ATI‑052, ATI‑2138 and ATI‑9494.
Aclaris Therapeutics (ACRS) reported Q3 2025 results. Total revenue was $3.299 million (contract research $0.485M; licensing $2.814M). Operating expenses rose on pipeline investment, with R&D at $13.028 million and G&A at $4.871 million. The company recorded non‑cash royalty income of $0.716 million from the OLUMIANT royalty sale structure.
Net loss was $14.614 million versus $7.586 million a year ago, reflecting higher development spend. Year‑to‑date, net loss was $45.128 million. The balance sheet showed cash, cash equivalents and marketable securities of $167.2 million as of September 30, 2025, and stockholders’ equity of $120.1 million. Management states its resources are sufficient for more than 12 months from issuance. Shares outstanding were 108,345,239 as of October 31, 2025.
Segment data highlight therapeutics as the primary driver: Q3 R&D included bosakitug $3.062M, ATI‑2138 $1.469M, and ATI‑052 $1.837M, alongside discovery $2.340M. Deferred income related to the royalty sale was $3.925M current and $17.492M non‑current.